Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AnaptysBio, Inc. filings document the company’s transition to a royalty management business and its Nasdaq-listed common stock under the symbol ANAB. Recent Form 8-K and 8-K/A filings cover the completed separation of First Tracks Biotherapeutics, related separation and transition services agreements, pro forma financial information, and material-event reporting tied to the new corporate structure.
The filing record also includes disclosures on operating and financial results, Regulation FD materials, stock repurchase authorizations, governance matters, and contract litigation involving the Jemperli Collaboration and Exclusive License Agreement. These documents frame AnaptysBio’s capital structure, collaboration rights, royalty-related business focus, and public-company reporting obligations.
AnaptysBio, Inc. reported insider equity activity by President and CEO Daniel Faga. On January 6, 2026, 17,850 restricted stock units (RSUs) were converted into the same number of shares of common stock for no cash consideration. On January 7, 2026, 9,202 shares of common stock were sold at $45.11 per share to cover tax withholding obligations related to RSU vesting, described as a non-discretionary “sell to cover” transaction.
Also on January 6, 2026, Faga received new equity awards consisting of 98,600 RSUs and a stock option for 133,400 shares with an exercise price of $43.91. The RSUs and option awards vest over several years, subject to continued service. After these transactions, Faga beneficially owned 466,787 shares of AnaptysBio common stock directly.
A shareholder of ANAB filed a Rule 144 notice to sell common stock. The planned sale covers 9,202 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $404,059.82 and an approximate sale date of January 7, 2026.
The shares were acquired as restricted stock units from the issuer on January 7, 2026 and paid for in cash. Over the prior three months, the same seller, Daniel Faga, sold 15,309 common shares on January 5, 2026 for gross proceeds of $688,139.55.
AnaptysBio, Inc. Chief Financial Officer Dennis Mulroy reported equity compensation activity and a related share sale. On January 6, 2026, 5,245 restricted stock units settled into common stock, and he then beneficially owned 19,575 common shares. On January 7, 2026, he sold 1,908 common shares at $45.11 per share to cover tax withholding tied to the RSU vesting, which the company notes was a non-discretionary sell-to-cover transaction, leaving him with 17,667 common shares.
On January 6, 2026, he also received new grants of 21,400 restricted stock units and 29,000 stock options with a $43.91 exercise price. The 21,400 RSUs vest 25% annually starting January 6, 2027, and the option vests 25% on January 6, 2027, then monthly in equal installments until fully vested, in each case contingent on continued service.
AnaptysBio investor Dennis Mulroy filed a Form 144 notice to sell 1,908 shares of the company’s common stock, with an aggregate market value of $83,780.28, through Morgan Stanley Smith Barney LLC on NASDAQ around January 7, 2026. These shares were acquired as restricted stock units from the issuer on January 7, 2026 and paid for in cash the same day. Common shares outstanding were 27,688,470.
Over the prior three months, the same seller reported additional common stock sales, including 3,363 shares on January 5, 2026 for gross proceeds of $1,511,166.85, 10,000 shares on December 22, 2025 for $500,000, and 15,725 shares on December 16, 2025 for $705,333.10. By signing the notice, the seller represents not knowing any undisclosed material adverse information about AnaptysBio’s current or prospective operations.
AnaptysBio director Dennis M. Fenton reported new equity awards. On January 6, 2026, he received a stock option for 5,500 shares of AnaptysBio common stock at an exercise price of $43.91 per share, held directly. The option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, conditioned on continued service.
On the same date, he was also granted 4,000 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock for no cash consideration. These RSUs vest in full on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service to the company.
AnaptysBio director Rita Jain reported new equity awards. On January 6, 2026, she received a stock option covering 5,500 shares of AnaptysBio common stock with an exercise price of $43.91 per share. According to the disclosure, this option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, so long as she continues to provide services to the company.
The filing also shows a grant of 4,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration upon settlement. These RSUs are scheduled to vest 100% on the date of AnaptysBio’s 2027 annual meeting of shareholders, again conditioned on continued service. After these awards, Jain beneficially owns 5,500 stock options and 4,000 RSUs directly.
AnaptysBio director Magda Marquet reported new equity awards from the company. On January 6, 2026, she received a stock option to buy 5,500 shares of AnaptysBio common stock at an exercise price of $43.91 per share. This option vests in equal 1/12 installments each month starting on February 6, 2026, as long as she continues providing service to the company on each vesting date.
On the same date, she was also granted 4,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration upon settlement. These RSUs vest as to 100% of the total award on the date of AnaptysBio’s 2027 annual meeting of shareholders, contingent on her continued service through that date.
AnaptysBio, Inc. director Renton Hollings received new equity awards on January 6, 2026. He was granted a stock option for 5,500 shares of AnaptysBio common stock at an exercise price of $43.91 per share, with no purchase price for the grant itself. This option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, so long as he continues to provide service on each vesting date.
He was also granted 4,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration upon settlement. These RSUs vest as to 100% of the 4,000 units on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service through that date.
AnaptysBio, Inc. reported a Form 4 for director John P. Schmid detailing new equity compensation awards. On January 6, 2026, he received a stock option covering 5,500 shares of common stock with an exercise price of $43.91 per share. This option vests in equal monthly installments of 1/12 starting February 6, 2026, so long as he continues providing service to the company.
Schmid was also granted 4,000 restricted stock units (RSUs), each representing the right to receive one share of AnaptysBio common stock for no cash payment. These RSUs vest 100% on the date of the company’s 2027 annual meeting of shareholders, contingent on his continued service through that date.
AnaptysBio, Inc. granted equity awards to director Ware J. Anthony. On 01/06/2026, he received a stock option for 5,500 shares of common stock with a $43.91 exercise price and no upfront cost. The option vests in 12 equal monthly installments of 1/12 each, starting on February 6, 2026, as long as he continues providing service to the company on each vesting date.
On the same date, he was also granted 4,000 restricted stock units. Each RSU represents a right to receive one share of AnaptysBio common stock for no consideration. All 4,000 RSUs are scheduled to vest in full on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service through that date.